IO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) Director Heidi Hunter bought 15,000 shares of the company's stock in a transaction on Friday, May 30th. The stock was bought at an average cost of $1.39 per share, with a total value of $20,850.00. Following the completion of the acquisition, the director now owns 15,000 shares of the company's stock, valued at $20,850. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.
IO Biotech Stock Up 3.4%
Shares of IOBT stock traded up $0.05 on Thursday, reaching $1.50. 110,586 shares of the stock were exchanged, compared to its average volume of 279,446. The stock has a market cap of $98.78 million, a P/E ratio of -1.09 and a beta of 0.09. IO Biotech, Inc. has a 1-year low of $0.66 and a 1-year high of $1.73. The firm has a 50 day moving average of $1.03 and a two-hundred day moving average of $0.95.
Wall Street Analyst Weigh In
IOBT has been the topic of a number of recent research reports. HC Wainwright reaffirmed a "buy" rating on shares of IO Biotech in a research note on Wednesday, May 14th. Piper Sandler raised IO Biotech to a "strong-buy" rating in a research note on Wednesday, March 12th.
Read Our Latest Report on IOBT
Hedge Funds Weigh In On IO Biotech
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vontobel Holding Ltd. acquired a new stake in IO Biotech during the 4th quarter valued at $30,000. Landscape Capital Management L.L.C. purchased a new position in IO Biotech in the 4th quarter valued at about $407,000. Renaissance Technologies LLC grew its stake in shares of IO Biotech by 22.5% during the fourth quarter. Renaissance Technologies LLC now owns 118,800 shares of the company's stock valued at $109,000 after acquiring an additional 21,800 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of IO Biotech during the fourth quarter worth about $26,000. Finally, Dauntless Investment Group LLC purchased a new position in IO Biotech in the fourth quarter valued at about $688,000. 54.76% of the stock is owned by institutional investors and hedge funds.
IO Biotech Company Profile
(
Get Free Report)
IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.
Further Reading
Before you consider IO Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IO Biotech wasn't on the list.
While IO Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
